Zelira Therapeutics Ltd’s (ASX:ZLD) (OTCQB: ZLDAF) (FRA:G1G) proprietary cannabinoid medicines, HOPE 1™ and HOPE 2™, are now available by prescription to patients in Australia through the Therapeutic Goods Administration’s (TGA) Special Access Scheme and through authorised prescribers.
The HOPE™ range of products will be distributed nationally via Health House Holdings.
Zelira Therapeutics managing director ex-USA Dr Richard Hopkins said: “Following the success of the HOPE™ launches in Pennsylvania and Louisiana, we are excited to make these products available to patients and physicians in Australia.
“This represents another key milestone in our commitment to bring the benefits of HOPE™ to patients in global markets.
“We believe HOPE™ can help support the unmet needs of the ASD community in Australia and look forward to working with all stakeholders to ensure they can access the benefits that medicinal cannabis can provide.”
Targets Autism Spectrum Disorder
HOPE™ is part of Zelira’s family of revenue-generating medicinal cannabis formulations.
The products consist of two pharmaceutical-grade proprietary formulations developed to target Autism Spectrum Disorder (ASD) as a disease indication.
The HOPE™ (HOPE 1 & 2) products were launched under licence to Ilera Healthcare in Pennsylvania in 2019 with the support of HOPE Grows for Autism, a leading autism advocacy group based in Pennsylvania.
HOPE™ has since established itself as one of the top-selling formulated medicinal cannabis products in Ilera Healthcare’s portfolio.
In August 2020, HOPE™ was launched under license in Louisiana in partnership with Advanced Biomedics LLC.